Application of magnolin in preparation of tumor drug resistance reversal agent

Through the combination of magnolitin and small molecule targeted drugs, the drug resistance of tumor cells is reversed, the problem of tumor cells' resistance to chemotherapy drugs is solved, the efficacy of chemotherapy is significantly improved, and new methods are provided for clinical treatment.

CN118924732APending Publication Date: 2024-11-12XI AN JIAOTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411362470.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-27
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

There is currently a lack of research on tumor resistance of magnolitin, which has led to tumor cells' resistance to chemotherapy drugs and reduced the efficacy of chemotherapy.

Method used

The combination of magnolitin and small-molecular targeted drugs (such as afatinib) is used to significantly reverse the drug resistance of tumor cells, inhibit the protein expression of epidermal growth factor receptors, promote cell apoptosis, and improve the sensitivity of chemotherapy drugs.

Benefits of technology

Magnolien significantly reverses the resistance of small-molecular targeted drugs, enhances its anti-tumor effect, provides new tumor treatment ideas, and improves the efficacy of chemotherapy and the quality of patients' survival.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924732A_ABST
    Figure CN118924732A_ABST
Patent Text Reader

Abstract

The invention discloses application of magnolin in preparation of a tumor drug resistance reversal agent, and discloses that magnolin can remarkably reverse the drug resistance, inhibit protein expression of an epidermal growth factor receptor and inhibit cell over-protection autophagy for the first time in a small molecule targeted drug resistance tumor cell strain. Magnolin can be developed into a drug for reversing multidrug resistance tumors by universally regulating the expression of drug-resistant protein, and an experimental basis and a theoretical basis are provided for the advantages of clinical combined targeted therapy drug application.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of natural product chemistry, and specifically relates to the application of magnolin in the preparation of a tumor drug resistance reversal agent. Background Art

[0002] Magnolin is a naturally occurring lignan molecule that is mainly extracted from Magnolia plants. It belongs to the lignan class of compounds and has a complex molecular structure. Its chemical formula is C 20 H 18 O6. Magnoliopsin has multiple biological activities and significant anti-inflammatory effects. It can inhibit the release of inflammatory mediators and reduce inflammatory responses. It can scavenge free radicals in the body and reduce the damage of oxidative stress to cells. It has an inhibitory effect on certain viruses and can interfere with the replication and spread of viruses. In recent years, the research on magnoliaopsin in anti-tumor has attracted widespread attention. The anti-tumor mechanisms of magnoliaopsin include: by inhibiting the ERK1 / 2 signaling pathway, magnoliaopsin can inhibit the proliferation and survival of tumor cells; activating caspase-3 and inducing programmed cell death of tumor cells; inhibiting cell proliferation and transformation by inhibiting the ERKs / RSK2 signaling pathway and interfering with the G1 / S cell cycle transition. Because magnoliaopsin has multiple biological activities, it has broad application prospects in anti-tumor, anti-inflammatory, antioxidant and antiviral aspects in the future. Especially in the field of anti-tumor, magnoliaopsin is expected to become a new treatment option.

[0003] Resistance reversal agents, also known as multidrug resistance (MDR) reversal agents, are a class of drugs that can overcome the multidrug resistance of tumor cells. The multidrug resistance of tumor cells can be divided into natural resistance (resistance that exists at the beginning of chemotherapy) and acquired resistance (induced by a chemotherapy drug during chemotherapy). Acquired resistance is related to a variety of mechanisms, including increased drug efflux, drug metabolism disorders, changes in drug targets, etc. Resistance reversal agents reverse this resistance through different mechanisms, thereby improving the efficacy of chemotherapy drugs.

[0004] At present, there is no research on the effect of magnolianoside on tumor drug resistance. By deeply studying the mechanism and effect of magnolianoside on tumor drug resistance, new ideas and methods can be provided for clinical treatment, and ultimately improve the survival rate and quality of life of tumor patients. Summary of the invention

[0005] In order to overcome the above-mentioned shortcomings of the prior art, the purpose of the present invention is to provide the use of magnoliavine in the preparation of tumor drug resistance reversal agents.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions: The invention discloses for the first time the application of magnolin in preparing a tumor drug resistance reversal agent.

[0007] Preferably, the tumor drug is a drug targeting tumor epidermal growth factor receptor.

[0008] Targeting tumors Epidermal growth factor receptor (EGFR) is a multifunctional glycoprotein widely distributed on the cell membranes of various tissues in the human body, playing a key role in cell growth, proliferation, differentiation, migration, apoptosis and other processes. EGFR is often overexpressed or mutated in a variety of solid tumors, leading to abnormal proliferation of tumor cells and abnormal signal transduction, and therefore becomes an important target for tumor treatment. EGFR plays an important role in the occurrence and development of a variety of tumors, including lung cancer, breast cancer, colorectal cancer, etc. Overexpression or mutation of EGFR can cause tumor cells to be overly sensitive to growth signals, thereby promoting tumor cell proliferation, invasion and metastasis. Therefore, inhibiting the activity of EGFR has become an important direction for tumor treatment. Tumor treatment strategies targeting EGFR mainly include two categories: small molecule tyrosine kinase inhibitors (TKI) and EGFR monoclonal antibodies.

[0009] More preferably, the tumor drug is a tyrosine kinase inhibitor.

[0010] Tyrosine kinase inhibitors (TKIs) are a class of compounds that can inhibit the activity of tyrosine kinases. Tyrosine kinases are a class of kinases that catalyze the transfer of γ-phosphate on ATP to protein tyrosine residues. They can catalyze the phosphorylation of tyrosine residues of various substrate proteins and play an important role in cell growth, proliferation, and differentiation. Tyrosine kinase inhibitors are an important class of anti-tumor drugs that inhibit the growth and proliferation of tumor cells and promote cell apoptosis mainly by inhibiting cell signal transduction.

[0011] More preferably, the tyrosine kinase inhibitor is a tyrosine kinase inhibitor.

[0012] Commonly used tyrosine kinase inhibitors in clinical practice include imatinib, sorafenib, nilotinib, dasatinib, etc. These drugs inhibit the growth and proliferation of tumor cells through different mechanisms and pathways. For example, imatinib is the first tyrosine kinase inhibitor used in clinical practice, mainly used to treat chronic myeloid leukemia; therefore, more preferably, the tyrosine kinase drugs of the present invention include afatinib, imatinib, dasatinib, ametinib, gefitinib, nilotinib, sunitinib, and osimertinib.

[0013] Preferably, the tumor drug is a small molecule targeted drug.

[0014] Small molecule targeted drugs are a class of chemically synthesized drugs that usually have a small molecular weight (less than 1000) and are composed of organic compounds. This type of drug plays an important role in tumor treatment, mainly by specifically acting on certain key proteins or enzymes in cells to block the proliferation and survival signals of cancer cells.

[0015] Preferably, the small molecule targeted drug comprises a chemically synthesized drug.

[0016] Preferably, the tumor drug is a drug that inhibits the expression of drug resistance-related proteins.

[0017] The invention also discloses an anti-tumor drug composition, which is composed of magnoliavine and small molecule targeted drugs.

[0018] Preferably, the small molecule targeted drug comprises a chemically synthesized drug.

[0019] Small molecule targeted drugs have many advantages over traditional chemotherapeutic drugs, such as lower toxicity, fewer side effects, more significant efficacy, etc. However, they also face some challenges, such as the development of drug resistance and the appearance of side effects. Therefore, the composition of the present invention can significantly reverse the drug resistance of small molecule targeted drugs through the combined use of magnolia linalool and small molecule targeted drugs, thereby better exerting its anti-tumor effect.

[0020] Compared with the prior art, the present invention has the following beneficial effects: The present invention reveals for the first time that magnolia resin can significantly reverse the drug resistance in tumor cell lines resistant to small molecule targeted drugs, and can inhibit the protein expression of epidermal growth factor receptor and inhibit cell over-protection autophagy. Experiments have confirmed that magnolia resin can be developed into a universal drug for regulating the expression of drug-resistant proteins and reversing multidrug-resistant tumors, providing an experimental basis and theoretical basis for the advantages of clinical combined targeted therapy drug applications. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 The results of the experiment on the inhibition of proliferation of lung cancer cell lines by magnolia oleracea; Figure 2 The experimental results of magnoliavine combined with afatinib inhibiting the proliferation of HCC827AR and NCI-H1975; Figure 3 The results of in vivo experiments on magnoliavine reversing drug resistance in HCC827AR cells; Figure 4 These are the in vivo experimental results of magnoliavine reversing the drug resistance of NCI-H1975 cells. DETAILED DESCRIPTION

[0022] In order to enable those skilled in the art to better understand the scheme of the present invention, the technical scheme in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.

[0023] It should be noted that the terms "first", "second", etc. in the specification and claims of the present invention and the above-mentioned drawings are used to distinguish similar objects, and are not necessarily used to describe a specific order or sequence. It should be understood that the data used in this way can be interchanged where appropriate, so that the embodiments of the present invention described herein can be implemented in an order other than those illustrated or described herein. In addition, the terms "including" and "having" and any variations thereof are intended to cover non-exclusive inclusions, for example, a process, method, system, product or device that includes a series of steps or units is not necessarily limited to those steps or units that are clearly listed, but may include other steps or units that are not clearly listed or inherent to these processes, methods, products or devices.

[0024] The present invention is further described in detail below in conjunction with the accompanying drawings: The magnolia oil used in the following examples of the present invention was purchased from Baoji Chenguang Biotechnology Co., Ltd., and the Herbest (Chenguang Biotechnology) product number batch is HM197535-150mg.

[0025] Example 1: Construction of small molecule targeted drug-resistant cell lines and evaluation of drug resistance coefficients In order to construct a small molecule targeted drug-resistant cell line, a high concentration shock method was used to construct afatinib (AR) acquired resistance cell line of non-small cell lung cancer cell HCC827. The parental non-small cell lung cancer cell line HCC827 in the logarithmic growth phase was selected and inoculated in a culture dish. The cell number was about 1×10 6 The cells were placed in an incubator (37°C, 5% CO2) for 12 h, and the culture medium was replaced with afatinib (4 μM). The cells were cultured until the logarithmic growth phase, and then trypsinized and centrifuged to collect the cells. 6 The cells were passaged at a density of 100 cells / dish into a medium containing drugs and induced to grow under this drug concentration condition for 6 to 9 months until the cells proliferated and grew normally in the medium with an afatinib concentration of 4 μM, thereby obtaining an afatinib-resistant non-small cell carcinoma strain HCC827AR.

[0026] AR resistance index (RI) = AR resistant cell IC 50 Value / AR sensitive cell IC 50 value Afatinib high concentration pulse method was used to induce non-small cell carcinoma parental cell line HCC827, and the HCC827 parental line was resistant to ARIC 50 The value was 16.57 nM; the IC value of the drug-resistant strain to AR 50 The value was 4.61 μM, and the drug resistance multiple was greater than 100 times, indicating that drug resistance had been fully formed and subsequent experimental investigations could be carried out.

[0027] Note: The resistance index can directly reflect the level of drug resistance of cells or pathogens. The higher the resistance index, the stronger the tolerance of drug-resistant cells to drugs, that is, the worse the therapeutic effect of drugs on the cells. In the process of new drug development, the resistance index can be used to evaluate the inhibitory effect of candidate drugs on drug-resistant strains, so as to screen out drugs with better resistance to drug resistance.

[0028] Example 2: Proliferation inhibition of magnoliavine on lung cancer cell lines The effect of the test drug on the proliferation of human lung cancer cells NCI-H1299, NCI-H1975, HCC827AR, and HCC827 was detected by the MTT test method. The cells in the exponential growth phase were digested with trypsin, blown into a single cell suspension, counted, and inoculated into a 96-well culture plate. After 24 h of culture in the incubator, different concentrations of test drugs were added after the cells adhered to the wall. After 48 h of action, the culture was terminated, and 20 μL of MTT (5 mg / mL) was added to each well, and incubated at 37 °C in the dark for 4 h. Then the liquid in each well was discarded, 150 μL of DMSO was added, and the crystals were shaken for 15 min to fully dissolve, and the cell optical density value was measured at a wavelength of 490 nm on an ELISA reader.

[0029] The results are as follows Figure 1 As shown, the cell inhibitory effect of the drug was detected by the above-mentioned MTT method. From the experimental results, it can be seen that the inhibitory effect of magnoliavine on the EGFR inhibitor-resistant cell line is better than that on the sensitive cell line.

[0030] Example 3: Experiment on the inhibition of proliferation of HCC827AR and NCI-H1975 by magnoliavine combined with afatinib Through the clone formation experiment, the effect of the test drug on the proliferation of human lung cancer cells NCI-H1975 and HCC827AR was detected. After the cells in the logarithmic growth phase were trypsinized, they were resuspended in complete medium (basal medium + 10% fetal bovine serum) into a cell suspension and counted. Inoculate 400-1,000 cells / well in each experimental group in a 6-well culture plate (determined according to the cell growth situation, generally 700 cells / well). Continue to culture until 14 days or until the number of cells in most single clones is greater than 50, change the medium every 3 days, and observe the cell state. After the cloning is completed, take pictures of the cells under a microscope, then wash once with PBS, add 1 mL of 4% paraformaldehyde to each well for 30-60 min, and wash once with PBS. Add 1 mL of crystal violet stain to each well and stain the cells for 10-20 min. Wash the cells several times with PBS, dry them, and take pictures with a digital camera (take pictures of the entire six-well plate and each well separately) See also Figure 2 From the results of clone formation, it can be seen that the addition of magnolia resin can greatly improve the sensitivity of cells to afatinib. This shows that the combined use of magnolia resin and afatinib can produce a synergistic effect and improve the sensitivity of drugs to cells (referring to the ability or degree of a drug to act on cells at a specific concentration, such as inhibiting, killing or changing its physiological function).

[0031] Example 4: In vivo experiment on reversal of drug resistance of HCC827AR cells by magnolia HC827AR cells were suspended in sterile physiological saline at a density of 2×107 cells / mL, and the cell suspension was inoculated subcutaneously in the right axilla of nude mice, 0.2 mL per mouse.

[0032] The mice were randomly divided into groups of 6 in each group in the second week after inoculation, and the drug concentration was designed according to the results of the acute toxicity experiment, and the drug was administered for 21 days according to the scheme. After the end of the drug administration, the mice were killed, the tumors were removed and weighed, and the inhibition rate of the drug on the growth of the nude mouse transplanted tumor was calculated.

[0033] The calculation formula of tumor inhibition rate is as follows:

[0034] The experimental data were expressed as mean ± standard error (Mean ± SEM) and analyzed using SPSS 19.0 statistical software. P < 0.05 indicated a significant difference.

[0035] Table 1. Results of the experiment on reversing afatinib resistance by magnoliavine in vivo

[0036] Compared with the negative control group,* P< 0.05, **** P< 0.0001 From Table 1 above and Figure 3 The results show that magnoliavine can effectively reverse the resistance of afatinib to HCC827AR cells in vivo.

[0037] Example 5: In vivo experiment on reversal of drug resistance of NCI-H1975 cells by magnolia NCI-H1975 cells were cultured at 2×10 7 The cells were suspended in sterile saline at a density of 100 / mL and inoculated subcutaneously in the right axilla of nude mice, 0.2 mL per mouse.

[0038] The mice were randomly divided into groups of 6 in each group in the second week after inoculation, and the drug concentration was designed according to the results of the acute toxicity experiment. The drug was administered for 12 days according to the scheme. After the end of the drug administration, the mice were killed, the tumors were removed and weighed, and the inhibition rate of the drug on the growth of the nude mouse transplanted tumor was calculated.

[0039] The calculation formula of tumor inhibition rate is as follows:

[0040] The experimental data were expressed as mean ± standard error (Mean ± SEM) and analyzed using SPSS 19.0 statistical software. P < 0.05 indicated a significant difference.

[0041] Table 2. Results of the experiment on reversing afatinib resistance by magnoliavine in vivo

[0042] Compared with the negative control group, ** P< 0.01, **** P< 0.0001 From Table 2 above and Figure 4 The results show that magnoliavine can effectively reverse the drug resistance of afatinib to NCI-H1975 cells in vivo.

[0043] In summary, the experimental results of Example 3 and Example 4 show that after the combined use of magnolia resin and afatinib, the tumor volume is significantly reduced and the growth process of the tumor is inhibited, indicating that magnolia resin can effectively reverse the drug resistance of afatinib in vivo, making the tumor sensitive to afatinib again and exerting anti-tumor efficacy. Therefore, it can be fully demonstrated that magnolia resin can be used as a tumor resistance reversal agent in the process of tumor treatment.

[0044] The above contents are only for explaining the technical idea of ​​the present invention and cannot be used to limit the protection scope of the present invention. Any changes made on the basis of the technical solution in accordance with the technical idea proposed by the present invention shall fall within the protection scope of the claims of the present invention.

Claims

1. Application of magnoliavine in the preparation of tumor drug resistance reversal agents.

2. The use according to claim 1, characterized in that The tumor drug is a drug targeting tumor epidermal growth factor receptor.

3. The use according to claim 2, characterized in that The tumor drug is a tyrosine kinase inhibitor.

4. The use according to claim 3, characterized in that The tyrosine kinase inhibitor is a tyrosine kinase inhibitor.

5. The use according to claim 4, characterized in that The tinib drugs include afatinib, imatinib, dasatinib, ametinib, gefitinib, nilotinib, sunitinib and osimertinib.

6. The use according to claim 1, characterized in that The tumor drug is a small molecule targeted drug.

7. The use according to claim 6, characterized in that The small molecule targeted drugs include chemically synthesized drugs.

8. An anti-tumor drug composition, characterized in that: It is composed of magnolia retinoids and small molecule targeted drugs.

9. The antitumor pharmaceutical composition according to claim 8, characterized in that: The small molecule targeted drugs include chemically synthesized drugs.

10. The antitumor pharmaceutical composition according to claim 8, characterized in that: The anti-tumor drug composition is also added with pharmaceutically acceptable excipients.